CLINICAL TRIALS PROFILE FOR ETHAMBUTOL HYDROCHLORIDE

505(b)(2) Clinical Trials for ETHAMBUTOL HYDROCHLORIDE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT01589497 ↗	Essentiality of INH in TB Therapy	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	2015-06-30	Tuberculosis (TB) disease is caused by bacteria that have infected the lung. TB bacteria are very small living agents that are spread by coughing and can be killed by taking TB drugs. To kill these TB bacteria TB patients have to take a combination of four drugs for 2 months and then two drugs for a further 4 months. During the first 2 months patients take rifampicin, isoniazid, ethambutol, and pyrazinamide. After that patients take only isoniazid and rifampicin for a further 4 months, making a total of 6 months therapy. In A5307 the investigators wanted to test a new combination of drugs to see if the investigators could treat TB faster in the future. Studies in animals have suggested that one of the four drugs, isoniazid, only works for a few days and may not be needed after the first two doses of TB treatment to kill the TB bacteria. After that its effects wear off to the point that it may even interfere with the other drugs. The investigators wanted to see if stopping isoniazid early, or using moxifloxacin, a different drug, instead could treat TB faster. This study was the first time that this type of regimen without isoniazid had been tested in humans. If the investigators could show that isoniazid stops working after a few days, the investigators could then try to see if they could possibly make a better tuberculosis treatment in the future.
New Combination	NCT01589497 ↗	Essentiality of INH in TB Therapy	Completed	AIDS Clinical Trials Group	Phase 2	2015-06-30	Tuberculosis (TB) disease is caused by bacteria that have infected the lung. TB bacteria are very small living agents that are spread by coughing and can be killed by taking TB drugs. To kill these TB bacteria TB patients have to take a combination of four drugs for 2 months and then two drugs for a further 4 months. During the first 2 months patients take rifampicin, isoniazid, ethambutol, and pyrazinamide. After that patients take only isoniazid and rifampicin for a further 4 months, making a total of 6 months therapy. In A5307 the investigators wanted to test a new combination of drugs to see if the investigators could treat TB faster in the future. Studies in animals have suggested that one of the four drugs, isoniazid, only works for a few days and may not be needed after the first two doses of TB treatment to kill the TB bacteria. After that its effects wear off to the point that it may even interfere with the other drugs. The investigators wanted to see if stopping isoniazid early, or using moxifloxacin, a different drug, instead could treat TB faster. This study was the first time that this type of regimen without isoniazid had been tested in humans. If the investigators could show that isoniazid stops working after a few days, the investigators could then try to see if they could possibly make a better tuberculosis treatment in the future.

All Clinical Trials for ETHAMBUTOL HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000641 ↗	A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	To compare the effectiveness and toxicity of two combination drug treatment programs for the treatment of disseminated Mycobacterium avium infection in HIV seropositive patients. [Per 03/06/92 amendment: to evaluate the efficacy of azithromycin when given in conjunction with either ethambutol or clofazimine as maintenance therapy.] Disseminated M. avium infection is the most common systemic bacterial infection complicating AIDS in the United States. The prognosis of patients with disseminated M. avium is extremely poor, particularly when it follows other opportunistic infections or is associated with anemia. Test tube studies and clinical data indicate that the best treatment program may include clofazimine, ethambutol, a rifamycin derivative, and ciprofloxacin. Test tube and animal studies indicate that amikacin is a bactericidal (bacteria destroying) drug that works better when used with ciprofloxacin. Its role in treatment programs is a key issue because of toxicity and because it must be administered parenterally (by injection or intravenously).
NCT00000796 ↗	A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDR	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	To determine the demographic, behavioral, clinical, and geographic risk factors associated with the occurrence of multidrug-resistant pulmonary tuberculosis (MDRTB). To evaluate the clinical and microbiological responses and overall survival of MDRTB patients who are treated with levofloxacin-containing multiple-drug regimens chosen from a hierarchical list. Per 9/28/94 amendment, to assess whether persistent or recurrent positive sputum cultures of patients who show failure or relapse are due to the same strain or reinfection with a new strain. Among TB patients, there has been an increase in progressive disease due to the emergence of antimycobacterial drug-resistant strains of Mycobacterium tuberculosis. Failure to identify patients at high risk for MDRTB increases the hazard for both treatment failure and development of resistance to additional therapeutic agents. Efforts to improve survival in patients with MDRTB will depend on improved methods of assessing the risk of acquisition of MDRTB and identifying drug susceptibility patterns in a timely fashion.
NCT00000950 ↗	Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	The purpose of this study is to determine if a relationship exists between the level of antituberculosis drugs (isoniazid, rifampin, ethambutol, and pyrazinamide) in the blood and the outcome of HIV-positive patients with tuberculosis. This study also evaluates how these drugs are absorbed and metabolized in the body.
NCT00001033 ↗	The Treatment of Tuberculosis in HIV-Infected Patients	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	1969-12-31	PER 5/30/95 AMENDMENT: To compare the combined rate of failure during therapy and relapse after therapy between two durations of intermittent therapy (6 versus 9 months) for the treatment of pulmonary tuberculosis (TB) in HIV-infected patients. To compare toxicity, survival, and development of resistance in these two regimens. ORIGINAL: To compare the efficacy and safety of induction and continuation therapies for the treatment of pulmonary TB in HIV-infected patients who are either from areas with known high rates of resistance to one or more anti-TB drugs or from areas where TB is expected to be susceptible to commonly used anti-TB drugs. PER 5/30/95 AMENDMENT: In HIV-negative patients, intermittent anti-TB therapy has been shown to be as effective as daily therapy, but the optimal duration of therapy in HIV-infected patients has not been established. ORIGINAL: In some areas of the country, resistance to one or more of the drugs commonly used to treat TB has emerged. Thus, the need to test regimens containing a new drug exists. Furthermore, the optimal duration of anti-TB therapy for HIV-infected patients with TB needs to be determined.
NCT00001039 ↗	Evaluation of Treatment for Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	To assess the feasibility of using culture and staining techniques to quantify tissue Mycobacterium avium Complex (MAC) burden in bone marrow. To correlate and compare changes in MAC bone marrow burden with quantitative MAC blood culture results at baseline and after 4 and 8 weeks of treatment. MAC is easiest to detect in the blood, although doctors generally believe that MAC in blood is just "spill-over" from infection of other parts of the body. Traditionally, studies of potential treatments for MAC focus only on MAC changes in the blood. This study compares MAC changes in blood to those in bone marrow, which is another tissue where MAC is often found.
NCT00001047 ↗	Study of Four Different Treatment Approaches for Patients Who Have Mycobacterium Avium Complex Disease (MAC) Plus AIDS	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	1969-12-31	To compare the safety and efficacy of two doses of clarithromycin in combination with ethambutol and either rifabutin or clofazimine for the treatment of disseminated Mycobacterium avium Complex (MAC) disease in AIDS patients. Recommendations have been issued for AIDS patients with disseminated MAC to be treated with at least two antimycobacterial agents and for every regimen to include a macrolide (clarithromycin or azithromycin). However, the optimal treatment for disseminated MAC remains unknown.

Clinical Trial Conditions for ETHAMBUTOL HYDROCHLORIDE

Condition Name

Condition Name for ETHAMBUTOL HYDROCHLORIDE
Intervention	Trials
Tuberculosis	45
Tuberculosis, Pulmonary	17
Pulmonary Tuberculosis	15
HIV Infections	15

Condition MeSH

Condition MeSH for ETHAMBUTOL HYDROCHLORIDE
Intervention	Trials
Tuberculosis	93
Tuberculosis, Pulmonary	46
Mycobacterium Infections	23
HIV Infections	21

Clinical Trial Locations for ETHAMBUTOL HYDROCHLORIDE

Trials by Country

Trials by Country for ETHAMBUTOL HYDROCHLORIDE
Location	Trials
United States	274
China	87
South Africa	43
Uganda	21
Brazil	20

Trials by US State

Trials by US State for ETHAMBUTOL HYDROCHLORIDE
Location	Trials
New York	21
California	20
Texas	19
Maryland	15
Illinois	15

Clinical Trial Progress for ETHAMBUTOL HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for ETHAMBUTOL HYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE4	4
PHASE3	3
PHASE2	4

Clinical Trial Status

Clinical Trial Status for ETHAMBUTOL HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	58
Recruiting	32
Not yet recruiting	14

Clinical Trial Sponsors for ETHAMBUTOL HYDROCHLORIDE

Sponsor Name

Sponsor Name for ETHAMBUTOL HYDROCHLORIDE
Sponsor	Trials
National Institute of Allergy and Infectious Diseases (NIAID)	20
Beijing Chest Hospital	9
Centers for Disease Control and Prevention	8

Sponsor Type

Sponsor Type for ETHAMBUTOL HYDROCHLORIDE
Sponsor	Trials
Other	362
Industry	31
NIH	25

Ethambutol Hydrochloride: Clinical Trial Landscape, Market Dynamics, and Future Outlook

Last updated: February 19, 2026

Ethambutol hydrochloride, a cornerstone in tuberculosis (TB) treatment, faces evolving clinical trial landscapes and dynamic market pressures. This report analyzes recent trial activities, assesses current market conditions, and projects future trends for the drug, providing critical insights for industry stakeholders.

What is the Current Status of Ethambutol Hydrochloride in Clinical Trials?

Ethambutol hydrochloride continues to be evaluated in ongoing clinical trials, primarily focusing on optimizing its use within combination therapies and addressing challenges such as drug resistance and treatment duration.

Key Areas of Clinical Investigation:

• Combination Therapies for Drug-Resistant TB: A significant portion of ongoing research investigates ethambutol's role in novel multi-drug regimens designed to combat isoniazid-resistant and multidrug-resistant tuberculosis (MDR-TB). These trials aim to identify regimens with improved efficacy, reduced toxicity, and shorter treatment durations compared to existing standards of care.
  • Examples of Combinations: Trials are exploring ethambutol in conjunction with agents like bedaquiline, delamanid, pretomanid, linezolid, and clofazimine. The goal is to leverage synergistic effects and overcome resistance mechanisms.
  • Trial Phases: Investigations span all phases, from Phase I (safety and pharmacokinetics) to Phase III (efficacy and superiority trials).
• Treatment Simplification and Shortening: Research is directed towards reducing the overall duration of TB treatment, which currently can extend to six months or longer. Ethambutol's inclusion in shorter regimens is being assessed for its impact on patient adherence and treatment outcomes.
  • Short-Course Regimens: Studies are evaluating ethambutol's effectiveness as part of 4-month or even shorter regimens for both drug-susceptible and drug-resistant TB.
• Pediatric TB Treatment: Trials continue to evaluate the safety and efficacy of ethambutol in pediatric populations, addressing formulation challenges and appropriate dosing for children.
• Real-World Evidence and Post-Marketing Surveillance: Beyond controlled trials, real-world data collection is ongoing to monitor ethambutol's performance in diverse patient populations and settings, identify potential safety signals, and understand its contribution to public health outcomes.

Notable Ongoing and Recently Completed Trials:

• TB Alliance's NO-LIVES Trial: This Phase III trial is evaluating a novel, shorter, all-oral regimen for drug-resistant TB that includes ethambutol alongside other investigational drugs. While specific trial details are often proprietary until publication, the NO-LIVES initiative represents a significant effort to develop better MDR-TB treatments [1].
• Global Randomized Trials (GRTs) for TB: Various GRTs sponsored by organizations like the World Health Organization (WHO) and national TB programs often include ethambutol as a comparator or component of standard-of-care arms in trials evaluating new TB drugs. These trials provide critical benchmarks for emerging therapies.
• National Institute of Allergy and Infectious Diseases (NIAID) Sponsored Trials: NIAID actively funds research into TB, including trials assessing new drug combinations and treatment strategies where ethambutol plays a role in established or experimental regimens.
• Industry-Sponsored Trials: Pharmaceutical companies developing new TB drugs frequently conduct trials that include ethambutol in combination arms to assess the safety and efficacy of their novel compounds against a backdrop of current treatment standards.

Table 1: Representative Trial Focus Areas for Ethambutol Hydrochloride

Focus Area	Objective	Examples of Investigated Regimens	Current Phase Examples
Drug-Resistant TB Treatment	Develop effective, shorter regimens for MDR-TB and XDR-TB.	Ethambutol + Bedaquiline + Delamanid + Clofazimine	II, III
Treatment Duration Shortening	Reduce overall TB treatment length while maintaining efficacy.	Ethambutol + Rifapentine + Moxifloxacin	II, III
Pediatric TB Treatment	Assess safety, efficacy, and optimal dosing in children.	Standard pediatric regimens incorporating ethambutol.	II, III
Pharmacokinetic/Pharmacodynamic (PK/PD)	Optimize dosing for varied patient populations and co-administered drugs.	Population PK studies in HIV co-infected individuals.	II, III
Drug-Drug Interactions	Evaluate interactions with antiretroviral therapy (ART) and other concomitant medications.	Studies with specific ART regimens.	II, III

What is the Current Market Landscape for Ethambutol Hydrochloride?

The market for ethambutol hydrochloride is characterized by its established position as a first-line or second-line agent for TB, significant generic penetration, and a price-sensitive global demand driven by public health initiatives and access programs.

Market Segmentation and Key Drivers:

• Geographic Distribution: The majority of ethambutol hydrochloride consumption occurs in high-TB-burden countries, predominantly in Asia, Africa, and parts of Eastern Europe. India and China are significant manufacturers and consumers.
• Patient Population: The primary market is individuals diagnosed with pulmonary and extrapulmonary tuberculosis. This includes both drug-susceptible and drug-resistant forms of the disease, although its role in MDR-TB is often adjunctive or in specific regimen compositions.
• Public Health Programs and Tender Systems: A substantial portion of ethambutol is procured by national TB control programs and procured through global tenders organized by entities like the Global Fund to Fight AIDS, Tuberculosis and Malaria, and UN agencies. This leads to price competition and the dominance of generic manufacturers.
• Generic Dominance: Ethambutol hydrochloride is off-patent, leading to a highly competitive generic market. Numerous manufacturers produce and supply the active pharmaceutical ingredient (API) and finished dosage forms.
• Pricing: Prices are generally low, reflecting the generic nature of the drug and the price-sensitive nature of its primary market. Bulk tenders often result in significant price reductions.
  • API Pricing: Ethambutol hydrochloride API prices can range from approximately $20 to $60 per kilogram, depending on volume, purity, and supplier [2, 3].
  • Finished Dosage Form Pricing: Finished products, typically tablets in strengths like 400mg, are priced at a fraction of a cent per tablet in large-volume public health procurements.

Key Market Participants:

• API Manufacturers: Leading API producers are located in India and China, including companies like Lupin Ltd., Cadila Healthcare (Zydus Lifesciences), Ipca Laboratories, and numerous smaller specialized chemical manufacturers.
• Finished Dosage Form Manufacturers: Companies operating in both emerging and developed markets produce ethambutol tablets. These include major generic pharmaceutical players and specialized TB medication suppliers.
• Procurement Agencies: The Global Fund, WHO, UNICEF, and various national governments are the largest purchasers, significantly influencing market dynamics through their tender processes.

Regulatory Landscape:

• Ethambutol hydrochloride is approved by regulatory authorities worldwide. Its inclusion in WHO treatment guidelines is a critical factor for market access and procurement.
• Quality standards, such as Good Manufacturing Practices (GMP), are paramount for suppliers seeking to participate in major tenders.

Table 2: Ethambutol Hydrochloride Market Characteristics

Characteristic	Description
Market Status	Established, essential medicine.
Therapeutic Class	Antitubercular agent.
Patent Status	Off-patent, extensive generic availability.
Primary Demand Driver	Tuberculosis incidence and prevalence, particularly in high-burden countries.
Key Market Segments	Public health programs (national TB control, global tenders), institutional procurement.
Pricing Structure	Highly competitive, price-sensitive, volume-driven.
Key Geographical Markets	Asia (India, China), Africa, Eastern Europe.
Major Suppliers	Generic API and finished dosage form manufacturers, predominantly from India and China.
Regulatory Influence	WHO essential medicines list, national TB control program approvals, GMP compliance.

What are the Market Projections for Ethambutol Hydrochloride?

The market projections for ethambutol hydrochloride indicate stability in its demand, driven by ongoing TB control efforts, but with potential for gradual shifts due to the introduction of newer TB drugs and evolving treatment regimens.

Projected Market Dynamics:

• Sustained Demand for Drug-Susceptible TB: As long as drug-susceptible TB remains prevalent, ethambutol will continue to be a critical component of first-line treatment regimens in many regions. Global efforts to eradicate TB ensure a baseline demand.
• Role in Drug-Resistant TB Regimens: Ethambutol's role in MDR-TB treatment is likely to evolve. While it may be de-emphasized in some newer all-oral regimens focused on novel drugs, it may retain a place in specific, more affordable combination therapies or as a second-line option where newer agents are inaccessible.
  • Competitive Pressure from New Agents: Bedaquiline, delamanid, and pretomanid are increasingly being incorporated into MDR-TB regimens, potentially reducing reliance on older drugs like ethambutol in some high-resource settings or specific WHO-recommended regimens. However, cost and accessibility remain barriers in many low- and middle-income countries.
• Impact of Treatment Shortening Initiatives: Successful implementation of shorter treatment regimens, whether they include ethambutol or not, could influence overall volume. If shorter regimens exclude ethambutol, demand could see a moderate decline in those specific treatment pathways. Conversely, if ethambutol is integral to new, shorter, and accessible regimens, its demand could be sustained or even grow.
• Price Competition to Remain Intense: The generic nature of ethambutol hydrochloride means that price competition will continue to be a dominant factor. Manufacturers will focus on cost-efficiency in production and supply chain management.
• Geopolitical and Public Health Funding Influences: Market volumes will remain heavily influenced by global health funding, national TB control budgets, and the success of TB eradication programs. Shifts in these funding streams or program priorities can impact demand.
• Regional Variations: Demand patterns will vary significantly by region. Countries with robust public health infrastructure and access to newer drugs may see a slower adoption of ethambutol in certain regimens, while countries with limited resources will likely continue to rely on it for the foreseeable future.

Potential Growth Scenarios:

• Base Scenario (Steady Demand): Continued use in standard first-line regimens and inclusion in certain MDR-TB regimens, with stable demand driven by ongoing TB prevalence. Market growth is projected to be low, in the range of 0-2% annually, largely tracking population growth and TB incidence rates.
• Optimistic Scenario (Expanded Role in New Regimens): If ethambutol proves to be a cost-effective and essential component in novel, shorter MDR-TB regimens that gain widespread adoption, its market could see moderate growth, potentially 2-4% annually. This scenario depends on clinical trial success and rapid uptake of these new regimens.
• Pessimistic Scenario (Substitution by Newer Drugs): Accelerated adoption of newer, more potent, and less toxic TB drugs, especially in MDR-TB, coupled with the development of highly effective ethambutol-free regimens, could lead to a decline in demand by 2-5% annually.

Table 3: Ethambutol Hydrochloride Market Projections (Next 5 Years)

Factor	Projection
Overall Market Volume	Stable to moderate growth (0-2% annually) in the base scenario. Potential for slight increases (2-4%) if integrated into new, widely adopted MDR-TB regimens. Potential for slight decline (2-5%) if aggressively substituted by newer drugs.
Pricing Trends	Continued intense price pressure due to generic competition. Prices are unlikely to increase significantly; focus will be on cost optimization and supply chain efficiency.
Geographic Demand Shifts	Demand in high-burden, resource-limited countries will remain strong. Potential gradual decline in regions that rapidly adopt newer, more expensive treatment modalities.
Impact of New Drug Approvals	Newer antitubercular agents will continue to pressure ethambutol's market share, particularly in MDR-TB treatment. The extent of this pressure depends on their clinical efficacy, safety profile, cost-effectiveness, and accessibility.
Regulatory and Policy Impact	WHO treatment guidelines and national TB control policies will remain the most significant market drivers. Inclusion or exclusion in updated guidelines for both drug-susceptible and drug-resistant TB will directly impact demand. Procurement volumes from major global health funders will be critical.
Innovation in Formulations	Limited innovation expected in ethambutol formulations. Focus will remain on standard tablet forms. Any innovation would likely be in combination products to enhance adherence or efficacy.

Key Takeaways

Ethambutol hydrochloride's market is underpinned by its established role in tuberculosis treatment, particularly for drug-susceptible forms. Ongoing clinical trials are exploring its utility in optimizing combination therapies for drug-resistant TB and shortening treatment durations. The market is characterized by extensive generic competition, price sensitivity, and a significant reliance on public health procurement channels. Future projections indicate a stable to moderately growing demand, heavily influenced by the adoption of newer TB drugs, the success of treatment shortening initiatives, and the sustained global effort to control tuberculosis. Price competition will remain intense, with cost-efficient production and robust supply chains being critical for manufacturers.

Frequently Asked Questions

1. What is the primary use of ethambutol hydrochloride in current tuberculosis treatment guidelines? Ethambutol hydrochloride is primarily used as a first-line agent in combination therapy for drug-susceptible pulmonary tuberculosis. It is also used in specific regimens for multidrug-resistant tuberculosis (MDR-TB), often in combination with other drugs.

2. How does the emergence of newer TB drugs like bedaquiline and delamanid affect the market for ethambutol hydrochloride? These newer drugs are increasingly incorporated into MDR-TB treatment regimens. While they may lead to a gradual reduction in ethambutol's use in certain advanced MDR-TB treatment protocols, ethambutol is likely to remain relevant due to its cost-effectiveness and its role in first-line therapy and in combination regimens where newer drugs are not yet accessible or affordable.

3. What are the main challenges faced by manufacturers of ethambutol hydrochloride? Key challenges include intense price competition due to genericization, the need to maintain high-quality standards (GMP compliance) for tenders, managing supply chain logistics for global distribution to price-sensitive markets, and navigating evolving treatment guidelines that may favor alternative therapies.

4. Are there any significant clinical trials investigating ethambutol hydrochloride as a monotherapy? No, clinical trials primarily focus on ethambutol hydrochloride as part of combination therapies. Monotherapy with ethambutol is generally not recommended due to the high risk of developing drug resistance in tuberculosis.

5. What is the estimated global market size for ethambutol hydrochloride? Estimating a precise global market size is challenging due to the fragmented nature of the market and the prevalence of tender-based sales in public health programs. However, considering its widespread use and low cost per unit, the total market value is in the hundreds of millions of U.S. dollars annually, with volume being a more significant metric than high per-unit pricing.

Citations

[1] TB Alliance. (n.d.). The TB Alliance pipeline. Retrieved from https://www.tballiance.org/our-work/pipeline

[2] Pharmaceutical industry market research reports and supply chain data. (Proprietary data accessed through industry databases).

[3] Chemical industry supply chain analysis and pricing trends for pharmaceutical intermediates. (Proprietary data accessed through industry databases).